R&D News | pharmaphorum

News

Thomas Appio, Bausch Health's chief executive

Bausch Health hit as Xifaxan successor flunks trials

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Pedestrian crossing green and red lights

MSD said to have pulled back from Revolution Meds deal

Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.

News

Nature: "Sidewinder" tech a leap forward in DNA synthesis

A new technology developed at Caltech represents a breakthrough in DNA synthesis, essentially allowing de novo sequence creation.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

Corxel's raises $287m for obesity drug, and other financings

Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

Bausch Health hit as Xifaxan successor flunks trials

MSD said to have pulled back from Revolution Meds deal

Nature: "Sidewinder" tech a leap forward in DNA synthesis

Sanofi plans amlitelimab dermatitis filing after new readout

Corxel's raises $287m for obesity drug, and other financings

Ovarian cancer data restores faith in Corcept's relacorilant

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks